|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GRM8 |
Gene summary for GRM8 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GRM8 | Gene ID | 2918 |
| Gene name | glutamate metabotropic receptor 8 | |
| Gene Alias | GLUR8 | |
| Cytomap | 7q31.33 | |
| Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | O00222 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2918 | GRM8 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.15e-03 | 6.54e-01 | -0.0811 |
| 2918 | GRM8 | HTA11_78_2000001011 | Human | Colorectum | AD | 9.09e-05 | 8.37e-01 | -0.1088 |
| 2918 | GRM8 | HTA11_866_2000001011 | Human | Colorectum | AD | 2.85e-02 | 4.24e-01 | -0.1001 |
| 2918 | GRM8 | HTA11_7696_3000711011 | Human | Colorectum | AD | 3.87e-05 | 4.38e-01 | 0.0674 |
| 2918 | GRM8 | HTA11_6818_2000001011 | Human | Colorectum | AD | 6.59e-09 | 1.13e+00 | 0.0112 |
| 2918 | GRM8 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.25e-25 | 1.50e+00 | 0.0588 |
| 2918 | GRM8 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 2.65e-18 | 1.60e+00 | 0.281 |
| 2918 | GRM8 | A002-C-010 | Human | Colorectum | FAP | 2.99e-08 | 5.97e-01 | 0.242 |
| 2918 | GRM8 | A001-C-207 | Human | Colorectum | FAP | 1.32e-11 | 7.95e-01 | 0.1278 |
| 2918 | GRM8 | A015-C-204 | Human | Colorectum | FAP | 6.52e-04 | 5.19e-01 | -0.0228 |
| 2918 | GRM8 | A002-C-203 | Human | Colorectum | FAP | 2.36e-07 | 4.76e-01 | 0.2786 |
| 2918 | GRM8 | A001-C-108 | Human | Colorectum | FAP | 6.60e-07 | 5.24e-01 | -0.0272 |
| 2918 | GRM8 | A001-C-104 | Human | Colorectum | FAP | 8.00e-23 | 8.57e-01 | 0.0184 |
| 2918 | GRM8 | A015-C-106 | Human | Colorectum | FAP | 3.63e-13 | 6.75e-01 | -0.0511 |
| 2918 | GRM8 | A015-C-104 | Human | Colorectum | FAP | 1.14e-02 | -5.67e-02 | -0.1899 |
| 2918 | GRM8 | A015-C-202 | Human | Colorectum | FAP | 1.17e-11 | 6.09e-01 | -0.0849 |
| 2918 | GRM8 | A001-C-014 | Human | Colorectum | FAP | 8.86e-14 | 7.05e-01 | 0.0135 |
| 2918 | GRM8 | A002-C-016 | Human | Colorectum | FAP | 7.23e-03 | 2.56e-01 | 0.0521 |
| 2918 | GRM8 | A015-C-002 | Human | Colorectum | FAP | 6.03e-13 | 8.13e-01 | -0.0763 |
| 2918 | GRM8 | A001-C-203 | Human | Colorectum | FAP | 1.08e-04 | 4.89e-01 | -0.0481 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0050804 | Colorectum | CRC | modulation of chemical synaptic transmission | 70/2078 | 439/18723 | 1.15e-03 | 1.33e-02 | 70 |
| GO:0099177 | Colorectum | CRC | regulation of trans-synaptic signaling | 70/2078 | 440/18723 | 1.23e-03 | 1.38e-02 | 70 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04724 | Colorectum | CRC | Glutamatergic synapse | 24/1091 | 115/8465 | 1.07e-02 | 4.74e-02 | 3.21e-02 | 24 |
| hsa047241 | Colorectum | CRC | Glutamatergic synapse | 24/1091 | 115/8465 | 1.07e-02 | 4.74e-02 | 3.21e-02 | 24 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GRM8 | SNV | Missense_Mutation | c.820N>C | p.Asn274His | p.N274H | O00222 | protein_coding | tolerated(0.08) | benign(0.078) | TCGA-A1-A0SN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | ac | SD | |
| GRM8 | SNV | Missense_Mutation | novel | c.727N>T | p.Gly243Cys | p.G243C | O00222 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A7-A6VY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| GRM8 | SNV | Missense_Mutation | c.2533N>T | p.Pro845Ser | p.P845S | O00222 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| GRM8 | SNV | Missense_Mutation | c.1859A>G | p.Glu620Gly | p.E620G | O00222 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GRM8 | SNV | Missense_Mutation | c.2630N>T | p.Pro877Leu | p.P877L | O00222 | protein_coding | deleterious(0) | probably_damaging(0.945) | TCGA-AN-A0XN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| GRM8 | SNV | Missense_Mutation | rs148553836 | c.1697N>A | p.Arg566His | p.R566H | O00222 | protein_coding | tolerated(0.38) | benign(0.02) | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| GRM8 | SNV | Missense_Mutation | novel | c.2413N>T | p.Ala805Ser | p.A805S | O00222 | protein_coding | tolerated(0.69) | benign(0.006) | TCGA-E9-A2JS-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamide | PD |
| GRM8 | insertion | Nonsense_Mutation | novel | c.1220_1221insCCATATCTCTACGTAGTC | p.Asp407_Ala408insHisIleSerThrTerSer | p.D407_A408insHIST*S | O00222 | protein_coding | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
| GRM8 | SNV | Missense_Mutation | rs553795874 | c.1141N>G | p.Ile381Val | p.I381V | O00222 | protein_coding | tolerated(0.68) | benign(0.006) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| GRM8 | SNV | Missense_Mutation | rs767201811 | c.1855C>T | p.Arg619Cys | p.R619C | O00222 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 2918 | GRM8 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 135650554 | EGLUMEGAD | |
| 2918 | GRM8 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | antagonist | 135650552 | ||
| 2918 | GRM8 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | allosteric modulator | 178102837 | ||
| 2918 | GRM8 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 135651136 | ||
| 2918 | GRM8 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | allosteric modulator | 381744920 | ||
| 2918 | GRM8 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 135650507 | ||
| 2918 | GRM8 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 135651511 | ||
| 2918 | GRM8 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 135650159 | ||
| 2918 | GRM8 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 135651501 | ||
| 2918 | GRM8 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME | agonist | 135650510 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |